A new ESGO ESTRO ESP 2021 classification for endometrial cancer has now included mutational analysis of POLE, MMR, and p53 immunohistochemistry testing in line with TCGA molecular-based classification for endometrial cancers. The gene discussed is TP53; the disease is endometrial cancer.